Mersana Therapeutics Inc.(MRSN),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

MRSN Mersana Therapeutics Inc.

Market Closed 09-27 16:00:00 EDT

1.85

+0.00

0.00%

盘后1.85

+0.000.00%

17:59 EDT

High1.91	Low1.83	Vol477.23K
Open1.90	D1 Closing1.85	Amplitude4.32%
Mkt Cap226.95M	Tradable Cap133.53M	Total Shares122.68M
T/O889.69K	T/O Rate0.66%	Tradable Shares72.18M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

{"stockData":{"symbol":"MRSN","market":"US","secType":"STK","nameCN":"Mersana Therapeutics Inc.","latestPrice":1.85,"timestamp":1727467200000,"preClose":1.85,"halted":0,"volume":477233,"hourTrading":{"tag":"盘后","latestPrice":1.85,"preClose":1.85,"latestTime":"17:59 EDT","volume":3483,"amount":6444.45,"timestamp":1727474340531},"delay":0,"floatShares":72178282,"shares":122675051,"eps":-0.863849,"marketStatus":"Market Closed","change":0,"latestTime":"09-27 16:00:00 EDT","open":1.9,"high":1.91,"low":1.83,"amount":889685.2628,"amplitude":0.043243,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-0.863849,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Market Trading","tradingStatus":1,"beginTime":1727683200000},"marketStatusCode":7,"adr":0,"adrRate":0,"listingDate":1498622400000,"exchange":"NASDAQ","adjPreClose":1.85,"preHourTrading":{"tag":"盘前","latestPrice":1.85,"preClose":1.85,"latestTime":"08:40 EDT","volume":150,"amount":277.5,"timestamp":1727440859501},"postHourTrading":{"tag":"盘后","latestPrice":1.85,"preClose":1.85,"latestTime":"17:59 EDT","volume":3483,"amount":6444.45,"timestamp":1727474340531},"volumeRatio":0.6684974450065346,"impliedVol":0.7661,"impliedVolPercentile":0.3254},"requestUrl":"/m/hq/s/MRSN","defaultTab":"news","newsList":[{"id":"2467881967","title":"Truist Financial Remains a Buy on Mersana Therapeutics (MRSN)","url":"https://stock-news.laohu8.com/highlight/detail?id=2467881967","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2467881967?lang=en_us&edition=fundamental","pubTime":"2024-09-16 19:16","pubTimestamp":1726485381,"startTime":"0","endTime":"0","summary":"In a report released today, Asthika Goonewardene from Truist Financial maintained a Buy rating on Mersana Therapeutics (MRSN – Research Report). Th...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/truist-financial-remains-a-buy-on-mersana-therapeutics-mrsn?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/truist-financial-remains-a-buy-on-mersana-therapeutics-mrsn?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","BK4563","MRSN"],"gpt_icon":0},{"id":"2466543699","title":"Truist Financial Releases a Buy Rating on Mersana Therapeutics (MRSN)","url":"https://stock-news.laohu8.com/highlight/detail?id=2466543699","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2466543699?lang=en_us&edition=fundamental","pubTime":"2024-09-10 19:16","pubTimestamp":1725966988,"startTime":"0","endTime":"0","summary":"Truist Financial analyst Asthika Goonewardene assigned a Buy rating to the stock today. The company’s shares closed yesterday at $1.50. According t...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/truist-financial-releases-a-buy-rating-on-mersana-therapeutics-mrsn?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/truist-financial-releases-a-buy-rating-on-mersana-therapeutics-mrsn?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MRSN"],"gpt_icon":0},{"id":"2459127995","title":"Mersana Therapeutics Is Maintained at Neutral by Baird","url":"https://stock-news.laohu8.com/highlight/detail?id=2459127995","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2459127995?lang=en_us&edition=fundamental","pubTime":"2024-08-14 19:51","pubTimestamp":1723636260,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/MRSN/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  August 14, 2024 07:51 ET (11:51 GMT)","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LENZ","MRSN"],"gpt_icon":0},{"id":"2459122909","title":"Truist Financial Issues a Buy Rating on Mersana Therapeutics (MRSN)","url":"https://stock-news.laohu8.com/highlight/detail?id=2459122909","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2459122909?lang=en_us&edition=fundamental","pubTime":"2024-08-14 19:28","pubTimestamp":1723634932,"startTime":"0","endTime":"0","summary":"Truist Financial analyst Asthika Goonewardene assigned a Buy rating to the stock today. The company’s shares closed yesterday at $1.35. According t...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/truist-financial-issues-a-buy-rating-on-mersana-therapeutics-mrsn?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/truist-financial-issues-a-buy-rating-on-mersana-therapeutics-mrsn?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MRSN"],"gpt_icon":0},{"id":"2459848154","title":"Investors Don't See Light At End Of Mersana Therapeutics, Inc.'s (NASDAQ:MRSN) Tunnel And Push Stock Down 32%","url":"https://stock-news.laohu8.com/highlight/detail?id=2459848154","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2459848154?lang=en_us&edition=fundamental","pubTime":"2024-08-14 03:08","pubTimestamp":1723576086,"startTime":"0","endTime":"0","summary":"Unfortunately for some shareholders, the Mersana Therapeutics, Inc. ( NASDAQ:MRSN ) share price has dived 32% in the...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-mrsn/mersana-therapeutics/news/investors-dont-see-light-at-end-of-mersana-therapeutics-incs-1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["QLD","MRSN","BK4588","BK4211","LU2210149790.SGD","NQmain",".IXIC","MNQmain","NDAQ","LU2210150020.SGD","TQQQ","IE00BKPKM429.USD","BK4112","QID","SQQQ","PSQ","BK4139","ISBC","LU2095319765.USD","BK4563","BK4585"],"gpt_icon":1},{"id":"2459418066","title":"TD Cowen Sticks to Its Buy Rating for Mersana Therapeutics (MRSN)","url":"https://stock-news.laohu8.com/highlight/detail?id=2459418066","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2459418066?lang=en_us&edition=fundamental","pubTime":"2024-08-14 01:36","pubTimestamp":1723570574,"startTime":"0","endTime":"0","summary":"TD Cowen analyst Tara Bancroft maintained a Buy rating on Mersana Therapeutics (MRSN – Research Report) today. The company’s shares opened today at...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/td-cowen-sticks-to-its-buy-rating-for-mersana-therapeutics-mrsn-2?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/td-cowen-sticks-to-its-buy-rating-for-mersana-therapeutics-mrsn-2?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MRSN","TD","COWN"],"gpt_icon":0},{"id":"2459904656","title":"Mersana Therapeutics, Inc. (MRSN) Reports Q2 Loss, Misses Revenue Estimates","url":"https://stock-news.laohu8.com/highlight/detail?id=2459904656","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2459904656?lang=en_us&edition=fundamental","pubTime":"2024-08-13 20:20","pubTimestamp":1723551605,"startTime":"0","endTime":"0","summary":"Mersana Therapeutics, Inc.  came out with a quarterly loss of $0.20 per share versus the Zacks Consensus Estimate of a loss of $0.18. This compares to loss of $0.47 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -11.11%. A quarter ago, it was expected that this company would post a loss of $0.18 per share when it actually produced a loss of $0.16, delivering a surprise of 11.11%.Over the last four quarters, the company has surpassed consensus EPS estimates two times.While Mersana Therapeutics has underperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock?Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Medical - Biomedical and Genetics is","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/T44Iwg7RbRrkaTIYz_liyQ--~B/aD00Njk7dz05MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/737ffb82e07dc8bffb77e72d153c91f2","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/T44Iwg7RbRrkaTIYz_liyQ--~B/aD00Njk7dz05MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/737ffb82e07dc8bffb77e72d153c91f2"],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/mersana-therapeutics-inc-mrsn-reports-122005212.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["MRSN"],"gpt_icon":0},{"id":"2459757249","title":"BRIEF-Mersana Therapeutics Q2 EPS USD -0.2","url":"https://stock-news.laohu8.com/highlight/detail?id=2459757249","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2459757249?lang=en_us&edition=fundamental","pubTime":"2024-08-13 19:00","pubTimestamp":1723546849,"startTime":"0","endTime":"0","summary":"Aug 13 (Reuters) - Mersana Therapeutics Q2 collaboration revenue USD 2.293 million. * Q2 net income USD -24.268 million","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MRSN","LENZ","USD"],"gpt_icon":0},{"id":"2459976602","title":"Mersana Therapeutics Inc -Continue to Expect to Announce Initial Xmt-1660 Clinical Data and Initiate Expansion in Second Half of 2024","url":"https://stock-news.laohu8.com/highlight/detail?id=2459976602","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2459976602?lang=en_us&edition=fundamental","pubTime":"2024-08-13 19:00","pubTimestamp":1723546804,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20240813:nTUA6JCKJX:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LENZ","BK4563","BK4139","MRSN"],"gpt_icon":0},{"id":"2459976503","title":"Mersana Therapeutics Inc -Capital Resources Expected to Support Current Operating Plan Commitments Into 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2459976503","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2459976503?lang=en_us&edition=fundamental","pubTime":"2024-08-13 19:00","pubTimestamp":1723546804,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20240813:nTUA6JCKJX:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4563","LENZ","BK4139","MRSN"],"gpt_icon":0},{"id":"2459975732","title":"Mersana Therapeutics Provides Business Update and Announces Second Quarter 2024 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2459975732","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2459975732?lang=en_us&edition=fundamental","pubTime":"2024-08-13 19:00","pubTimestamp":1723546804,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20240813:nTUA6JCKJX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LENZ","BK4139","MRSN","BK4563"],"gpt_icon":0},{"id":"2459597608","title":"Mersana Therapeutics Provides Business Update and Announces Second Quarter 2024 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2459597608","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2459597608?lang=en_us&edition=fundamental","pubTime":"2024-08-13 19:00","pubTimestamp":1723546800,"startTime":"0","endTime":"0","summary":"Dose escalation advancing in Phase 1 clinical trials of both XMT-1660 and XMT-2056 Continue to expect to announce initial XMT-1660 clinical data and initiate expansion in the second half of 2024 Capit","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2024/08/13/2929034/0/en/Mersana-Therapeutics-Provides-Business-Update-and-Announces-Second-Quarter-2024-Financial-Results.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4563","BK4139","MRSN","LENZ"],"gpt_icon":0},{"id":"2457046840","title":"Mersana Therapeutics to Host Second Quarter 2024 Conference Call on August 13, 2024","url":"https://stock-news.laohu8.com/highlight/detail?id=2457046840","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2457046840?lang=en_us&edition=fundamental","pubTime":"2024-08-06 20:00","pubTimestamp":1722945600,"startTime":"0","endTime":"0","summary":"CAMBRIDGE, Mass., Aug.  06, 2024  (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2024/08/06/2925026/0/en/Mersana-Therapeutics-to-Host-Second-Quarter-2024-Conference-Call-on-August-13-2024.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4585","MRSN","HST","BK4181","BK4563","BK4588","LENZ","BK4218"],"gpt_icon":0},{"id":"2456436412","title":"Mersana Therapeutics (NASDAQ:MRSN) shareholders have endured a 83% loss from investing in the stock three years ago","url":"https://stock-news.laohu8.com/highlight/detail?id=2456436412","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2456436412?lang=en_us&edition=fundamental","pubTime":"2024-08-01 21:54","pubTimestamp":1722520458,"startTime":"0","endTime":"0","summary":"As every investor would know, not every swing hits the sweet spot. But really big losses can really drag down an overall portfolio. So consider, for a moment, the misfortune of Mersana Therapeutics, Inc.  investors who have held the stock for three years as it declined a whopping 83%. That would be a disturbing experience. Shareholders have had an even rougher run lately, with the share price down 42% in the last 90 days. While a drop like that is definitely a body blow, money isn't as important as health and happiness.Check out our latest analysis for Mersana Therapeutics. Mersana Therapeutics isn't currently profitable, so most analysts would look to revenue growth to get an idea of how fast the underlying business is growing. Generally speaking, companies without profits are expected to grow revenue every year, and at a good clip. That's because it's hard to be confident a company will be sustainable if revenue growth is negligible, and it never makes a profit.Over three years, Mers","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/d3vISzLZXw94x30FKv9beA--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/4d522452d0da08d8412701a84270533b","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/d3vISzLZXw94x30FKv9beA--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/4d522452d0da08d8412701a84270533b"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/mersana-therapeutics-nasdaq-mrsn-shareholders-135418115.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["QLD","QID","BK4563","TQQQ","BK4588","LU2095319765.USD","LU2210150020.SGD","BK4585","LU2210149790.SGD","NDAQ","IE00BKPKM429.USD","NQmain","BK4139","SQQQ","BK4112","MNQmain",".IXIC","PSQ","MRSN"],"gpt_icon":1},{"id":"2437358264","title":"Mersana Therapeutics to Present at Upcoming Investor Conferences","url":"https://stock-news.laohu8.com/highlight/detail?id=2437358264","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2437358264?lang=en_us&edition=fundamental","pubTime":"2024-05-22 12:00","pubTimestamp":1716350400,"startTime":"0","endTime":"0","summary":"CAMBRIDGE, Mass., May  22, 2024  (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2024/05/22/2886458/0/en/Mersana-Therapeutics-to-Present-at-Upcoming-Investor-Conferences.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4563","LENZ","BK4139","MRSN"],"gpt_icon":0},{"id":"2437148743","title":"SBRA, GH and CRBU are among after hour movers","url":"https://stock-news.laohu8.com/highlight/detail?id=2437148743","media":"seekingalpha","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2437148743?lang=en_us&edition=fundamental","pubTime":"2024-05-21 04:47","pubTimestamp":1716238067,"startTime":"0","endTime":"0","summary":"Gainers: Maravai LifeSciences (MRVI) +5%.Caribou Biosciences (CRBU) +4%.Greenidge Generation Holdings (GREE) +4%.Cipher Mining (CIFR) +4%.SIGA Technologies (SIGA) +4%.Losers: Pulmonx Corporation (LUNG) -5%.Longboard Pharmaceuticals (LBPH) -5%.Mersana Therapeutics (MRSN) -5%.Sabra Health Care REIT (SBRA) -2%.Guardant Health (GH) -2%.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/news/4108543-sbra-gh-and-crbu-are-among-after-hour-movers","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"seekingalpha","symbols":["BK4583","LBPH","BK4196","BK4551","BK4225","SBRA","BK4563","BK4007","BK4535","BK4023","CFA.SI","BK4139","MRVI","BK4588","BK4121","SIGA","BK4082","MRSN","BK4585","BK4198","LUNG","GH","CIFR","CRBU","BK4203","GREE","BK4539","BK4595"],"gpt_icon":0},{"id":"2435665555","title":"Mersana Therapeutics: On Hold While Waiting For Any Positive News","url":"https://stock-news.laohu8.com/highlight/detail?id=2435665555","media":"seekingalpha","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2435665555?lang=en_us&edition=fundamental","pubTime":"2024-05-15 21:56","pubTimestamp":1715781360,"startTime":"0","endTime":"0","summary":"Mersana Therapeutics, Inc. is a cancer-focused biotech with two pipeline projects in phase 1 clinical study.Their lead compounds, XMT-1660 and XMT-2056, target novel immune checkpoints and HER2, respe","market":"sh","thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1712655074/image_1712655074.jpg","type":0,"news_type":0,"thumbnails":["https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1712655074/image_1712655074.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/article/4693433-mersana-therapeutics-on-hold-while-waiting-for-any-positive-news","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"seekingalpha","symbols":["BK4139","BK4563","LENZ","MRSN"],"gpt_icon":0},{"id":"2435514773","title":"Truist Financial Sticks to Its Buy Rating for Mersana Therapeutics (MRSN)","url":"https://stock-news.laohu8.com/highlight/detail?id=2435514773","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2435514773?lang=en_us&edition=fundamental","pubTime":"2024-05-14 22:05","pubTimestamp":1715695508,"startTime":"0","endTime":"0","summary":"Truist Financial analyst Asthika Goonewardene reiterated a Buy rating on Mersana Therapeutics (MRSN – Research Report) today and set a price target...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/truist-financial-sticks-to-its-buy-rating-for-mersana-therapeutics-mrsn?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/truist-financial-sticks-to-its-buy-rating-for-mersana-therapeutics-mrsn?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4563","MRSN","BK4139"],"gpt_icon":0},{"id":"2435594638","title":"Analysts Are Bullish on These Healthcare Stocks: Mersana Therapeutics (MRSN), Insulet (PODD)","url":"https://stock-news.laohu8.com/highlight/detail?id=2435594638","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2435594638?lang=en_us&edition=fundamental","pubTime":"2024-05-14 19:30","pubTimestamp":1715686239,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Mersana Therapeutics (MRSN – Research Report), Insul...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-are-bullish-on-these-healthcare-stocks-mersana-therapeutics-mrsn-insulet-podd?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-are-bullish-on-these-healthcare-stocks-mersana-therapeutics-mrsn-insulet-podd?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4585","BK4137","MRSN","BK4551","BK4566","BK4139","BK4082","BK4563","PODD","BK4588","HCSG"],"gpt_icon":0},{"id":"2435655598","title":"Analysts Have Conflicting Sentiments on These Healthcare Companies: Mersana Therapeutics (MRSN), Insulet (PODD) and Crispr Therapeutics AG (CRSP)","url":"https://stock-news.laohu8.com/highlight/detail?id=2435655598","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2435655598?lang=en_us&edition=fundamental","pubTime":"2024-05-14 17:40","pubTimestamp":1715679609,"startTime":"0","endTime":"0","summary":"Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Mersana Therapeutics (MRSN – Research Report), Ins...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-have-conflicting-sentiments-on-these-healthcare-companies-mersana-therapeutics-mrsn-insulet-podd-and-crispr-therapeutics-ag-crsp?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-have-conflicting-sentiments-on-these-healthcare-companies-mersana-therapeutics-mrsn-insulet-podd-and-crispr-therapeutics-ag-crsp?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4551","BK4139","AG","MRSN","PODD","CRSP","LU1861558580.USD","BK4588","LU1861559042.SGD","BK4566","BK4082","BK4210","BK4585","BK4563","HCSG","BK4556","BK4137"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.mersana.com","stockEarnings":[{"period":"1week","weight":-0.1435},{"period":"1month","weight":0.2416},{"period":"3month","weight":-0.0796},{"period":"6month","weight":-0.5871},{"period":"1year","weight":0.4567},{"period":"ytd","weight":-0.2026}],"compareEarnings":[{"period":"1week","weight":0.0056},{"period":"1month","weight":0.0235},{"period":"3month","weight":0.05},{"period":"6month","weight":0.0924},{"period":"1year","weight":0.3335},{"period":"ytd","weight":0.2022}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Mersana Therapeutics, Inc., a clinical stage biopharmaceutical company, develops antibody drug conjugates (ADC) for cancer patients with unmet needs. The company develops XMT-1660, a B7-H4-targeted Dolasynthen ADC candidate; and XMT-2056, an immunosynthen ADC. It has research and development collaborations with Janssen Biotech, Inc., Ares Trading S.A., Merck KGaA, and Asana BioSciences, LLC for the development of ADC product candidates. The company was formerly known as Nanopharma Corp. and changed its name to Mersana Therapeutics, Inc. in November 2005. Mersana Therapeutics, Inc. was incorporated in 2001 and is headquartered in Cambridge, Massachusetts.","yearOnYearQuotes":[{"month":1,"riseRate":0.571429,"avgChangeRate":0.019423},{"month":2,"riseRate":0.571429,"avgChangeRate":0.173916},{"month":3,"riseRate":0,"avgChangeRate":-0.165787},{"month":4,"riseRate":0.428571,"avgChangeRate":0.027646},{"month":5,"riseRate":0.428571,"avgChangeRate":0.275375},{"month":6,"riseRate":0.285714,"avgChangeRate":-0.078008},{"month":7,"riseRate":0.25,"avgChangeRate":-0.160523},{"month":8,"riseRate":0.5,"avgChangeRate":0.058223},{"month":9,"riseRate":0.25,"avgChangeRate":-0.098538},{"month":10,"riseRate":0.285714,"avgChangeRate":-0.038493},{"month":11,"riseRate":0.571429,"avgChangeRate":0.214233},{"month":12,"riseRate":0.428571,"avgChangeRate":0.053714}],"exchange":"NASDAQ","name":"Mersana Therapeutics Inc.","nameEN":"Mersana Therapeutics Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.28.1","shortVersion":"4.28.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Mersana Therapeutics Inc.(MRSN),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Mersana Therapeutics Inc.(MRSN) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Mersana Therapeutics Inc.,MRSN,Mersana Therapeutics Inc.股票,Mersana Therapeutics Inc.股票老虎,Mersana Therapeutics Inc.股票老虎国际,Mersana Therapeutics Inc.行情,Mersana Therapeutics Inc.股票行情,Mersana Therapeutics Inc.股价,Mersana Therapeutics Inc.股市,Mersana Therapeutics Inc.股票价格,Mersana Therapeutics Inc.股票交易,Mersana Therapeutics Inc.股票购买,Mersana Therapeutics Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Mersana Therapeutics Inc.(MRSN),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Mersana Therapeutics Inc.(MRSN) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}